Clinical and prophylactic trials with assured new treatment for those at greater risk: II. Examples.
Authors:
- B LevinBLB Levin
- H RobbinsHRH Robbins
- 1 May 1996
- journal article
- research article
- Published by American Public Health Association in American Journal of Public Health
- Vol. 86 (5) , 696-705
Abstract
OBJECTIVES: The preceding article proposed an assured treatment design that would address certain difficulties in recruiting persons who are at greater risk into randomized clinical trials. The purpose of this article is to illustrate the statistical validity of the design in a practical setting. METHODS: Three actual randomized clinical trials were considered as case studies; in each, the data that would have been obtained under assured allocation were identified. Then, with only these data, together with a reasonable choice of model describing the response of subjects under standard treatment as a function of initial severity, the treatment effect was estimated for the subjects at greater risk. The estimates were compared with conventional estimates for the sicker patients randomized in the original trials. RESULTS: In each case, the estimates produced in the assured treatment trial were close to those observed in the randomized trial. CONCLUSIONS: Risk-based allocation trials deserve serious consideration when randomized clinical trials are difficult or impossible to execute. The proposed designs and analyses would allow physicians to offer persons at greater risk assurance that they would receive the new treatment, while researchers would retain the ability to draw valid statistical conclusions about treatment efficacy.Keywords
This publication has 10 references indexed in Scilit:
- Clinical and prophylactic trials with assured new treatment for those at greater risk: I. A design proposal.American Journal of Public Health, 1996
- Adjusting for Differential Rates of Prophylaxis Therapy for PCP in High-Versus Low-Dose AZT Treatment Arms in an AIDS Randomized TrialJournal of the American Statistical Association, 1994
- A Controlled Trial Comparing Continued Zidovudine with Didanosine in Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1992
- Estimating a multiplicative treatment effect under biased allocationBiometrika, 1991
- Compliance as an Explanatory Variable in Clinical TrialsJournal of the American Statistical Association, 1991
- A Randomized Controlled Trial of a Reduced Daily Dose of Zidovudine in Patients with the Acquired Immunodeficiency SyndromeNew England Journal of Medicine, 1990
- Estimating the superiority of a drug to a placebo when all and only those patients at risk are treated with the drug.Proceedings of the National Academy of Sciences, 1989
- The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart diseaseJAMA, 1984
- The Lipid Research Clinics Coronary Primary Prevention Trial ResultsJAMA, 1984
- Statistical Models and Methods for Lifetime DataTechnometrics, 1983